FIG. 1

POTASSIUM DICLOFENAC

Formulation A - Average Value of the 6 volunteers




FIG. 2

POTASSIUM DICLOFENAC

Formulation B - Average Value of the 6 volunteers




FIG. 3

POTASSIUM DICLOFENAC

Formulation C - Average Value of the 6 volunteers





FIG. 4


POTASSIUM DICLOFENAC

Formulation A - B - C - Average Value of the 6 volunteers




Mean, overlaid plasma concentration-time curves measured in all v lunteers after administration of diclofenac test and reference formulations in linear and 1 g-scale.

Dose administered = 50 mg.



Mean, overlaid plasma concentration-time profiles measured in all volunteers after administration of diclofenac T₁, T₂, R₁ (CATAFLAM³) and R₂ (VOLTAROL³) formulations; linear and log scales.



n-tim profil of dicl fenac measured in all v lunteers after oral administrati n fT1 f rmulati n. Lin ar scal . V rtical bars are SD.






FIGURE 8 Mean plasma concentration-time profile of diclofenac measured in all volunteers after oral administration of T₂ formulation. Linear scale. Vertical bars are SD.



Mean plasma c ncentration-tim profil f diclofenac measured in all v lunteers after oral administrati n of R (VOLTARENE® RAPIDE) formulati n. Linear scale. V rtical bars are SD.



Mean, overlaid plasma concentration-time profile of diclofenac measured in all volunteers after oral administration of T₁, T₂ and R (VOLTARENE® RAPIDE) formulation. Linear and log scales.

FIGURE 10

